ArticleNews reportPHN-05502026-11-02 02:39 CT

Taking Wegovy, Ozempic? Abu Dhabi study reveals economic benefits of weight-loss drugs

Source · Khaleej Times

TLDR

NYU Abu Dhabi researchers analysing Danish records linked semaglutide treatment to employment and working-hour gains. They reported a 4.1-percentage-point increase in employment probability among subsidised Ozempic patients and 29.7 additional working hours per quarter among already-employed Wegovy patients.

01—Key points

01Researchers analysed Danish population records from 2018–2024, comparing employment, hours and earnings before and after treatment.
02Ozempic patients recorded 19.5 additional working hours per quarter; Wegovy patients showed no significant increase in entering employment.
03The study’s fiscal analysis suggested additional income tax revenue could help offset public spending on subsidised diabetes treatment.

Why it matters Editorial

The findings suggest semaglutide’s economic evaluation may extend beyond medication costs to employment outcomes and public revenue.

Read the original at Khaleej Times↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.